A detailed history of Morgan Stanley transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,246,892 shares of IBRX stock, worth $5.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,246,892
Previous 568,401 295.3%
Holding current value
$5.89 Million
Previous $3.59 Million 132.04%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.32 - $6.7 $5.57 Million - $11.2 Million
1,678,491 Added 295.3%
2,246,892 $8.34 Million
Q2 2024

Oct 17, 2024

SELL
$4.82 - $9.15 $270,884 - $514,230
-56,200 Reduced 9.0%
568,401 $3.59 Million
Q2 2024

Aug 14, 2024

SELL
$4.82 - $9.15 $270,884 - $514,230
-56,200 Reduced 9.0%
568,401 $3.59 Million
Q1 2024

Oct 17, 2024

BUY
$3.23 - $6.17 $181,526 - $346,754
56,200 Added 9.89%
624,601 $3.35 Million
Q1 2024

Aug 16, 2024

BUY
$3.23 - $6.17 $80,372 - $153,528
24,883 Added 4.15%
624,601 $3.35 Million
Q1 2024

May 15, 2024

BUY
$3.23 - $6.17 $80,372 - $153,528
24,883 Added 4.15%
624,601 $3.35 Million
Q4 2023

Aug 16, 2024

BUY
$1.25 - $5.21 $39,146 - $163,161
31,317 Added 5.51%
599,718 $3.01 Million
Q4 2023

Feb 13, 2024

BUY
$1.25 - $5.21 $252,271 - $1.05 Million
201,817 Added 50.72%
599,718 $3.01 Million
Q3 2023

Nov 15, 2023

BUY
$1.29 - $3.1 $60,957 - $146,487
47,254 Added 13.48%
397,901 $672,000
Q2 2023

Aug 14, 2023

SELL
$1.53 - $6.41 $341,372 - $1.43 Million
-223,119 Reduced 38.89%
350,647 $974,000
Q1 2023

May 15, 2023

BUY
$1.35 - $4.78 $39,970 - $141,526
29,608 Added 5.44%
573,766 $1.04 Million
Q4 2022

Feb 14, 2023

SELL
$4.35 - $6.77 $424,799 - $661,124
-97,655 Reduced 15.22%
544,158 $2.76 Million
Q3 2022

Nov 14, 2022

SELL
$3.65 - $6.43 $1.23 Million - $2.17 Million
-336,830 Reduced 34.42%
641,813 $3.19 Million
Q2 2022

Oct 27, 2022

SELL
$2.68 - $6.14 $254,267 - $582,538
-94,876 Reduced 8.84%
978,643 $3.64 Million
Q2 2022

Aug 15, 2022

SELL
$2.68 - $6.14 $254,267 - $582,538
-94,876 Reduced 8.84%
978,643 $3.64 Million
Q1 2022

Oct 27, 2022

BUY
$5.05 - $7.53 $479,123 - $714,416
94,876 Added 9.69%
1,073,519 $6.02 Million
Q1 2022

May 13, 2022

BUY
$5.05 - $7.53 $3.24 Million - $4.82 Million
640,695 Added 148.03%
1,073,519 $6.02 Million
Q4 2021

Feb 14, 2022

SELL
$5.67 - $10.18 $367,983 - $660,682
-64,900 Reduced 13.04%
432,824 $2.63 Million
Q3 2021

Nov 15, 2021

BUY
$9.17 - $14.24 $4.56 Million - $7.09 Million
497,724 New
497,724 $4.85 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.05B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.